Showing results (381-390 of 504) with videos related to

Sort By:
Pageof 51
Biorxiv : the Preprint Server for Biology|February 17, 2023
MGA deletion leads to Richter's transformation via modulation of mitochondrial OXPHOSPrajish Iyer, Bo Zhang, Tingting Liu, et al.
The Journal of Pharmacology and Experimental Therapeutics|October 1, 1993
Pharmacology of CP-99,994; a nonpeptide antagonist of the tachykinin neurokinin-1 receptorS McLean, A Ganong, P A Seymour, et al.
Nucleic Acids Research|December 6, 2018
ITCH nuclear translocation and H1.2 polyubiquitination negatively regulate the DNA damage responseLufen Chang, Lei Shen, Hu Zhou, et al.
Blood|November 1, 1983
Estrogen receptor analysis in chronic lymphocytic leukemiaS T Rosen, Z Maciorowski, F Wittlin, et al.
Tumour Biology : the Journal of the International Society for Oncodevelopmental Biology and Medicine|January 1, 1989
Immunohistochemical analysis of pulmonary and pleural tumors with the monoclonal antibody HYB-612 directed against the multidrug resistance (MDR-1) gene product, P-glycoproteinJ A Radosevich, P G Robinson, L S Rittmann-Grauer, et al.
International Journal of Molecular Sciences|June 24, 2022
Arsenic Trioxide and Venetoclax Synergize against AML Progenitors by ROS Induction and Inhibition of Nrf2 ActivationDinh Hoa Hoang, Ralf Buettner, Melissa Valerio, et al.
International Journal of Radiation Applications and Instrumentation. Part B, Nuclear Medicine and Biology|January 1, 1989
Stability of radioiodinated monoclonal antibodies: in vitro storage and plasma analysisA M Zimmer, J M Kazikiewicz, D I Webber, et al.
Blood|February 8, 2022
Targeting macrophages for enhancing CD47 blockade-elicited lymphoma clearance and overcoming tumor-induced immunosuppressionXu Cao, Yingyu Wang, Wencan Zhang, et al.
Leukemia Research|September 17, 2022
Dual targeting fixed duration frontline monoclonal antibody therapy for chronic lymphocytic leukemia: A phase 2 studyShuo Ma, Steven T Rosen, Maria Winqvist, et al.
British Journal of Haematology|August 10, 2013
A phase I/II trial of bortezomib combined concurrently with gemcitabine for relapsed or refractory DLBCL and peripheral T-cell lymphomasAndrew M Evens, Steven T Rosen, Irene Helenowski, et al.
Pageof 51